Related references
Note: Only part of the references are listed.Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
A. T. Shaw et al.
ANNALS OF ONCOLOGY (2013)
A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer
Mark A. Socinski et al.
CLINICAL CANCER RESEARCH (2013)
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2013)
Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
Eamon M. Berge et al.
CLINICAL LUNG CANCER (2013)
Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
Thomas H. Marsilje et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
High-Dose Pemetrexed in Combination with High-Dose Crizotinib for the Treatment of Refractory CNS Metastases in ALK-Rearranged Non-Small-Cell Lung Cancer
Leena Gandhi et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Clinical Impact of Continued Crizotinib Administration after Isolated Central Nervous System Progression in Patients with Lung Cancer Positive for ALK Rearrangement
Masayuki Takeda et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
Monica Ceccon et al.
MOLECULAR CANCER RESEARCH (2013)
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study
Takashi Seto et al.
LANCET ONCOLOGY (2013)
Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer
Ha Yeon Lee et al.
LUNG CANCER (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy
M. Takeda et al.
ANNALS OF ONCOLOGY (2012)
The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers
A. J. Atherly et al.
BRITISH JOURNAL OF CANCER (2012)
Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer
June Koo Lee et al.
CANCER (2012)
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement
Hye Ryun Kim et al.
CANCER (2012)
Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer
Robert C. Doebele et al.
CANCER (2012)
Isolated central nervous system progression on Crizotinib An Achilles heel of non-small cell lung cancer with EML4-ALK translocation?
Stephen G. Chun et al.
CANCER BIOLOGY & THERAPY (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK-Positive Non-Small Cell Lung Cancer
Junko Tanizaki et al.
CLINICAL CANCER RESEARCH (2012)
Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
Johannes M. Heuckmann et al.
CLINICAL CANCER RESEARCH (2012)
Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice A French Study
Anne McLeer-Florin et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge et al.
LANCET ONCOLOGY (2012)
Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients
Heae Surng Park et al.
LUNG CANCER (2012)
Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer A proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma
Jin Ho Paik et al.
LUNG CANCER (2012)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Hiroshi Sakamoto et al.
CANCER CELL (2011)
Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
Christine M. Lovly et al.
CANCER RESEARCH (2011)
Targeting Anaplastic Lymphoma Kinase in Lung Cancer
Alice T. Shaw et al.
CLINICAL CANCER RESEARCH (2011)
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
Daniel B. Costa et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer Correlation with Fluorescence In Situ Hybridization
Jin Ho Paik et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma Suggestion for an Effective Screening Strategy for These Tumors
Youngil Koh et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma IHC Score Algorithm for FISH
Eunhee S. Yi et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Ryohei Katayama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer
Heather R. Sanders et al.
CANCER GENETICS (2011)
Evaluation of EML4-ALK Fusion Proteins in Non-Small Cell Lung Cancer Using Small Molecule Inhibitors
Yongjun Li et al.
NEOPLASIA (2011)
Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4-ALK Fusion Gene
Tsuyoshi Takahashi et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
Mari Mino-Kenudson et al.
CLINICAL CANCER RESEARCH (2010)
Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
D. Ross Camidge et al.
CLINICAL CANCER RESEARCH (2010)
Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The EML4-ALK Fusion Gene Is Involved in Various Histologic Types of Lung Cancers From Nonsmokers With Wild-type EGFR and KRAS
Daisy Wing-Sze Wong et al.
CANCER (2009)
KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
Kengo Takeuchi et al.
CLINICAL CANCER RESEARCH (2009)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
ALK Gene Rearrangements A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer
Benjamin Solomon et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset
Kentaro Inamura et al.
MODERN PATHOLOGY (2009)
Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer
Young Lim Choi et al.
CANCER RESEARCH (2008)
Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer
Hiroyuki Mano
CANCER SCIENCE (2008)
Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts
Kengo Takeuchi et al.
CLINICAL CANCER RESEARCH (2008)
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
Jussi P. Koivunen et al.
CLINICAL CANCER RESEARCH (2008)
The anaplastic lymphoma kinase in the pathogenesis of cancer
Roberto Chiarle et al.
NATURE REVIEWS CANCER (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Oncogenic shock: Explaining oncogene addiction through differential signal attenuation
Sreenath V. Sharma et al.
CLINICAL CANCER RESEARCH (2006)
Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer
AS Tsao et al.
CANCER (2006)
Share Paper
